JP2017504570A5 - - Google Patents

Download PDF

Info

Publication number
JP2017504570A5
JP2017504570A5 JP2016534640A JP2016534640A JP2017504570A5 JP 2017504570 A5 JP2017504570 A5 JP 2017504570A5 JP 2016534640 A JP2016534640 A JP 2016534640A JP 2016534640 A JP2016534640 A JP 2016534640A JP 2017504570 A5 JP2017504570 A5 JP 2017504570A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
tauopathy
composition according
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016534640A
Other languages
English (en)
Japanese (ja)
Other versions
JP6629201B2 (ja
JP2017504570A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/067360 external-priority patent/WO2015081085A2/en
Publication of JP2017504570A publication Critical patent/JP2017504570A/ja
Publication of JP2017504570A5 publication Critical patent/JP2017504570A5/ja
Application granted granted Critical
Publication of JP6629201B2 publication Critical patent/JP6629201B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016534640A 2013-11-27 2014-11-25 タウオパチーの処置方法 Expired - Fee Related JP6629201B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361909965P 2013-11-27 2013-11-27
US61/909,965 2013-11-27
PCT/US2014/067360 WO2015081085A2 (en) 2013-11-27 2014-11-25 Methods of treating a tauopathy

Publications (3)

Publication Number Publication Date
JP2017504570A JP2017504570A (ja) 2017-02-09
JP2017504570A5 true JP2017504570A5 (https=) 2017-09-28
JP6629201B2 JP6629201B2 (ja) 2020-01-15

Family

ID=52232410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016534640A Expired - Fee Related JP6629201B2 (ja) 2013-11-27 2014-11-25 タウオパチーの処置方法

Country Status (9)

Country Link
US (2) US20160289309A1 (https=)
EP (1) EP3074420A2 (https=)
JP (1) JP6629201B2 (https=)
CN (2) CN111569063A (https=)
BR (1) BR112016010454A2 (https=)
CA (1) CA2931396C (https=)
EA (1) EA038994B1 (https=)
MX (2) MX384909B (https=)
WO (1) WO2015081085A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150646A1 (es) 2012-08-16 2015-05-21 Ipierian Inc Metodos de tratamiento de una tauopatia
US12024568B2 (en) 2012-09-13 2024-07-02 Cornell University Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
EP4465050A3 (en) 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
WO2017100632A1 (en) * 2015-12-11 2017-06-15 Arizona Board Of Regents On Behalf Of Arizona State University Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CN117820467A (zh) 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
MA48595A (fr) 2016-12-07 2020-03-18 Ac Immune Sa Anticorps anti-tau et leurs méthodes d'utilisation
BR112019017021A2 (pt) 2017-02-17 2020-04-14 Denali Therapeutics Inc anticorpos anti-tau e métodos de uso dos mesmos
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
US20190135905A1 (en) * 2017-06-16 2019-05-09 Bristol-Myers Squibb Company Compositions and methods for treating tauopathies
MX2019015071A (es) * 2017-06-16 2020-02-13 Bristol Myers Squibb Co Composiciones y metodos para tratar tauopatias.
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antibodies recognizing tau
GB202010652D0 (en) * 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
CN115607684A (zh) * 2021-07-15 2023-01-17 华中科技大学 一种内耳药物纳米载体及其应用
TW202334201A (zh) * 2021-11-03 2023-09-01 日商衛材R&D企管股份有限公司 抗Ｔａｕ抗體之組成物、劑型及方法
WO2025196217A1 (en) * 2024-03-21 2025-09-25 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
AU4188196A (en) 1994-12-22 1996-07-10 Nissan Chemical Industries Ltd. Organobismuth derivatives and process for producing the same
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
ES2166097T5 (es) 1996-08-27 2007-03-16 Novartis Vaccines And Diagnostics, Inc. Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
AR014621A1 (es) 1997-12-12 2001-03-28 Macromed Inc Un poli (etilenglicol) con forma de estrella, heterofuncional, biocompatible, metodo para su obtencion y metodo para conjugarlo con una proteina
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
BRPI0923283A2 (pt) 2008-12-05 2017-06-06 Angiochem Inc conjugados terapêuticos de peptídeo e usos dos mesmos
CA3239368A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
EP2470211B1 (en) * 2009-08-28 2016-01-27 The Board of Regents of The University of Texas System Antibodies that bind tau oligomers
DK2496594T3 (en) * 2009-11-06 2018-03-05 The J David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS
ES2548686T3 (es) * 2010-10-07 2015-10-20 Ac Immune S.A. Anticuerpos que reconocen fosfo-Tau
BR112013008765B8 (pt) * 2010-10-11 2023-05-02 Biogen Idec Int Neuroscience Gmbh Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
ES2656442T3 (es) * 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
PE20150646A1 (es) * 2012-08-16 2015-05-21 Ipierian Inc Metodos de tratamiento de una tauopatia

Similar Documents

Publication Publication Date Title
JP2017504570A5 (https=)
AR104875A1 (es) Anticuerpos anti-tau y métodos de uso
Dunning et al. Can Parkinson's disease pathology be propagated from one neuron to another?
WO2014058924A3 (en) Antibodies recognizing alpha-synuclein
MX356800B (es) Anticuerpo tau humanizado.
NZ748983A (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
IL266911B2 (en) Anti-tau antibodies and uses thereof in treating tauopathy, retaining or increasing cognitive memory capacity or slowing memory loss
JP2017502920A5 (https=)
JP2014502141A5 (https=)
JP2018519810A5 (https=)
JP2018505651A5 (https=)
JP2017532288A5 (https=)
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
NZ739181A (en) Anti-pyroglutamated amyloid beta humanized antibodies
AU2017291414B2 (en) Anti-N3pGLu amyloid beta peptide antibodies and uses thereof
WO2018175752A8 (en) Optimized antibody compositions for treatment of ocular disorders
IL225568A (en) Phospho-specific antibodies for tau detection
RU2017103446A (ru) УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ
MX2021014274A (es) Moleculas de union anti-tdp-43 y usos de las mismas.
WO2014204816A3 (en) Method for assessing protein identity and stability
WO2014160871A8 (en) Methods and agents for treating alzheimer's disease
Kroksveen et al. Cerebrospinal fluid proteomics in multiple sclerosis
JP2018535921A5 (https=)
Roca et al. Chronic neurological disorders and related comorbidities: role of age-associated physiological changes
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use